G2 checkpoint kinase inhibitors exert their radiosensitizing effects prior to the G2/M transition

Area of Science:

• Oncology
• Molecular Biology
• Cell Cycle Regulation

Background:

• Chemical inhibitors targeting the G2 checkpoint can enhance cancer cell sensitivity to DNA damage.
• These inhibitors are thought to induce cell death by forcing division with unrepaired DNA.
• Several G2 checkpoint inhibitors are in preclinical and clinical development for cancer therapy.

Purpose of the Study:

• To investigate the effects of ATM/ATR inhibitor caffeine and Chk1 inhibitor isogranulatimide on p53-defective cancer cell survival after ionizing radiation.
• To determine the optimal timing for administering these inhibitors to achieve radiosensitization.
• To elucidate the role of G2 checkpoint abrogation versus S-phase inhibition in radiosensitizing p53-defective cells.

Main Methods:

• Utilized two p53-defective cell lines: MCF7-mp53 and HCT-116 p53-/-.
• Administered caffeine and isogranulatimide at various time points after ionizing radiation exposure.
• Assessed clonogenic survival as a measure of cell killing.

Main Results:

• Administering inhibitors 16-24 hours post-irradiation (during maximal G2 arrest) led to premature mitosis but increased clonogenic survival.
• Radiosensitization was most effective when inhibitors were given between 2 and 16 hours after irradiation, coinciding with S-phase progression.
• Inhibition of S-phase ATM/ATR and Chk1 activities appeared more critical for radiosensitization than G2 checkpoint abrogation.

Conclusions:

• The timing of inhibitor administration significantly impacts the outcome of radiosensitization in p53-defective cancer cells.
• Inhibiting S-phase DNA damage response pathways may be a more effective strategy than targeting the G2 checkpoint for radiosensitization.
• Optimized scheduling of combination treatments involving ATM/ATR and Chk1 inhibitors is essential for achieving synergistic anti-tumor effects in vivo.